$CRL

AI Analysis

Generated on May 11, 2026

AI Score
58/ 100
Hold$CRL

Charles River Laboratories

$CRLNYSEHealthcareMid-Cap

Charles River provides drug discovery and development services including preclinical and clinical laboratory services.

Market Cap
$10.0B
Revenue (TTM)
$4.0B
-3.0%
Net Income (TTM)
$0.3B
-10.0%
EPS (TTM)
$5.50
P/E Ratio
28.0
Dividend Yield
0.0%
52-Week Range
$155-$275
Beta
1.15
Dimension Scores
Fundamental
56
Technical
56
Sentiment
60
Risk / Reward
62
Momentum
50
FundTechSentRiskMome
Financial Health
Profitability
61moderate
Growth
53weak
Liquidity
70strong
Solvency
58moderate
Efficiency
54moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $CRL

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.